MarketPulse
A

$ATAI

5 articles found
5 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Ataibeckley Inc.

AtaiBeckley's Oral MDMA Therapy Shows Promise in Social Anxiety, Outperforming Placebo

AtaiBeckley reports Phase 2a results for EMP-01 oral R-MDMA in social anxiety disorder, showing 49% responder rates and 38% symptom reduction versus 15% on placebo.
ATAIclinical trial resultssocial anxiety disorder
GlobeNewswire Inc.GlobeNewswire Inc.··Ataibeckley Inc.

AtaiBeckley CEO to Present at Needham Conferences as Psychedelic Drug Advances

AtaiBeckley will showcase its FDA-designated breakthrough therapy BPL-003 at Needham conferences in April, advancing toward Phase 3 trials in 2026.
ATAItreatment-resistant depressionFDA Breakthrough Therapy Designation
GlobeNewswire Inc.GlobeNewswire Inc.··Ataibeckley Inc.

AtaiBeckley's BPL-003 Shows Durable Antidepressant Benefits in Treatment-Resistant Depression

AtaiBeckley's BPL-003 nasal spray demonstrates rapid and sustained antidepressant effects in treatment-resistant depression Phase 2a trial, advancing toward Phase 3 launch in Q2 2026.
ATAIPhase 3 clinical trialtreatment-resistant depression
GlobeNewswire Inc.GlobeNewswire Inc.··Ataibeckley Inc.

AtaiBeckley Secures FDA Nod for Phase 3 Depression Trial, Eyes 2029 Runway

AtaiBeckley advances psychedelic depression treatment to Phase 3 with $220.7M cash runway through early 2029, plus positive anxiety trial data.
ATAIPhase 3 clinical trialFDA approval
BenzingaBenzinga··Prnewswire

Psychedelic Drug Developers Entering Final Testing Phase for Mental Health Treatments

Five biotech firms advance psychedelic therapies to Phase 3 trials for depression and anxiety, with multiple readouts expected in 2026, marking progress toward regulatory approval.
ATAIDFTXGHRSLBRXpsychedelic biotechnologyPhase 3 trials